High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose

Transfusion

Volumn 42, Issue 4, 2002, Pages 443-450

  Lefrère, François ^a,b   Delarue, Richard ^a,b   Somme, Dominique ^a,b   Levy, Vincent ^a,b   Damaj, Gandhi ^a,b   Tu, Angela ^a,b   Porcher, Raphael ^a,b   Audat, Françoise ^a,b   Boulat, Claire ^a,b   Cavazzana Calvo, Marine ^a,b   Buzyn, Agnès ^a,b   Belanger, Coralie ^a,b   Maillard, Natacha ^a,b   Hermine, Olivier ^a,b   Varet, Bruno ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD COMPONENT THERAPY; CELL COUNT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CYTOLOGY; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; THROMBOCYTE TRANSFUSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BLOOD COMPONENT TRANSFUSION; CELL COUNT; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPHILS; PLATELET TRANSFUSION; TRANSPLANTATION CONDITIONING;

EID: 19044378030     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2002.00060.x     Document Type: Article

References (20)

1. 1 Kessinger A, Armitage JO, Landmark JD, et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988 ; 71: 723 ‐ 7.
2. 2 Hohaus S, Goldschmit H, Ehrhardt R, Haas R. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG‐CSF. Exp Hematol 1993 ; 21: 508 ‐ 14.
3. 3 Brugger W, Birken R, Bertz H, et al. Peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony stimulating factor accelerate both neutrophil and platelet recovery after high‐dose VP16, ifosfamide and cisplatin. Br J Haematol 1993 ; 84: 402 ‐ 7.
4. 4 Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony‐stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high‐dose chemotherapy. Blood 1993 ; 81: 2031 ‐ 5.
5. 5 Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high‐dose chemotherapy using autologous peripheral‐blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995 ; 13: 1328 ‐ 35.
6. 6 Schmitz N, Linch DC, Dreger P, et al. A randomised trial of filgrastim‐mobilised peripheral blood progenitor cell transplantation versus autologous bone‐marrow transplantation in lymphoma patients. Lancet 1996 ; 347: 353 ‐ 7.
7. 7 To LB, Roberts MM, Haylock DN, et al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogenic bone marrow transplants. Bone Marrow Transplant 1992 ; 9: 277 ‐ 84.
8. 8 Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994 ; 83: 3787 ‐ 94.
9. 9 Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995 ; 86: 3961 ‐ 9.
10. 10 Benedetti G, Patoia L, Giglietti A, et al. Very large amounts of peripheral blood progenitor cell eliminate severe thrombocytopenia after high‐dose melphalan in advanced breast cancer patients. Bone Marrow Transplant 1999 ; 24: 971 ‐ 9.
11. 11 Drake M, Ranaghan L, Morris TC, et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997;98:745‐9; erratum in Br J Haematol 1997;99:479.
12. 12 Lefrère F, Makki J, Marolleau JP, et al. CD34+ cells during leukapheresis procedures: relationship of volume processed and quantity of peripheral blood progenitor cells collected. Transfusion 2000 ; 40: 493 ‐ 4. DOI: 10.1046/j.1537-2995.2000.4004493.x
13. 13 Ajani JR, Welch SR, Raber MN, et al. Comprehensive criteria for assessing therapy‐induced toxicity. Cancer Invest 1990 ; 8: 147 ‐ 59.
14. 14 Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral‐blood stem cells. J Clin Oncol 1995 ; 13: 2547 ‐ 55.
15. 15 Ketterer N, Salles G, Raba M, et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998 ; 91: 3148 ‐ 55.
16. 16 Schulman KA, Birch R, Zhen B, et al. Effect of CD34+ cell dose on resource utilization in patients after high‐dose chemotherapy with peripheral‐blood stem cell support. J Clin Oncol 1999 ; 17: 1227 ‐ 33.
17. 17 Siena S, Shiavo R, Pedrazzoli P, Carlo‐Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000 ; 18: 1360 ‐ 77.
18. 18 Pilarski L, Hipperson G, Seeberger K, et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self‐renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000 ; 95: 1056 ‐ 65.
19. 19 Weaver CH, Potz J, Redmond J, et al. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Bone Marrow Transplant 1997 ; 19: 1103 ‐ 10.
20. 20 Perez‐Simon JA, Caballero MD, Corral M, et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998 ; 38: 385 ‐ 91.